Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C

Yoshiaki Iwasaki, Hiroshi Ikeda, Yasuyuki Araki, Toshiya Osawa, Keiji Kita, Masaharu Ando, Toshinari Shimoe, Kouichi Takaguchi, Noriaki Hashimoto, Toshitsugu Kobatake, Minoru Tomita, Mitsuhiko Kawaguchi, Haruhiko Kobashi, Kohsaku Sakaguchi, Yasushi Shiratori – 22 December 2005 – In contrast to the United States, Japanese patients with chronic hepatitis C currently treated with interferon are generally 10 to 15 years older. Older patients, however, tend to experience more frequent adverse events.

Systemic hemodynamics, vasoactive systems, and plasma volume in patients with severe Budd‐Chiari syndrome

Manuel Hernández‐Guerra, Eric López, Pablo Bellot, Carlos Piera, Juan Turnes, Juan G. Abraldes, Jaime Bosch, Juan C. García‐Pagán – 22 December 2005 – Budd‐Chiari syndrome (BCS) causes postsinusoidal portal hypertension, which leads to complications similar to those observed in cirrhosis. However, no studies have investigated whether patients with BCS develop the hyperdynamic circulatory syndrome present in patients with cirrhosis who have portal hypertension.

Parenteral nutrition–associated liver disease and the role for isolated intestine and intestine/liver transplantation

Alan L. Buchman, Kishore Iyer, Jonathan Fryer – 22 December 2005 – Parenteral nutrition–associated liver disease (PNALD) is the most devastating complication of long‐term parenteral nutrition therapy. Because its progression is typically insidious and its long‐term consequences are generally underappreciated, PNALD is often recognized too late, when liver injury is irreversible.

Subscribe to